Renalytix to work on chronic disease strategies with AstraZeneca
By Iain Gilbert
Date: Friday 21 Aug 2020
(Sharecast News) - Artificial intelligence diagnostics company Renalytix AI revealed on Friday that it will collaborate with pharmaceutical giant AstraZeneca to help improve outcomes for patients with chronic disease.
The pair will look to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases, with the first stage in the collaboration using artificial intelligence-enabled in vitro diagnostic platform KidneyIntelX to examine further improving outcomes for patients with chronic kidney disease and its complications,
The goal of the first stage, undertaken in coordination with the Mount Sinai Health System, was to help improve guideline-based standard-of-care for optimal utilisation of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software.
Renalytix's Dr Barbara Murphy said: "We believe this collaboration will define how we can leverage KidneyIntelX to improve the care and outcomes for patients affected by chronic diseases, such as kidney disease, diabetes, and cardiovascular disease.
"By using a more personalised approach, our initial goal is to help realise improved outcomes for more than 240,000 patients with chronic kidney disease within the Mount Sinai Health System."
As of 1050 BST, Renalytix shares were up 10.72% at 625.55p.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN